Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Unlocking efficiency in drug discovery: GE Healthcare’s The Pulse visits Sygnature Discovery

The Pulse recently interviewed Dr Scott Pollack, Associate Director, Biophysics and Enzymology, and Dr Paul Clewlow, Senior VP, Business Development, about how Sygnature Discovery is accelerating their ambitious clients’ drug discovery programs and helping them to increase their productivity through the application of cutting-edge technology, such as the Biacore 8K surface plasmon resonance equipment that was recently added to Sygnature’s Bioscience Department.

To read The Pulse article, go to:

Latest News

View All

Senior appointments enhance Sygnature Discovery’s DMPK capabilities

The creation of ScanStation; drug discovery takes…

Sygnature Discovery starts 2019 with two senior…

Pathios Therapeutics and Sygnature Discovery sign strategic…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.